ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
This Quarter Return
+13.5%
1 Year Return
+45.88%
3 Year Return
+300.28%
5 Year Return
+633.15%
10 Year Return
–
AUM
$71.7M
AUM Growth
+$71.7M
(+33%)
Cap. Flow
+$10.9M
Cap. Flow
% of AUM
15.14%
Top 10 Holdings %
Top 10 Hldgs %
66.95%
Holding
32
New
12
Increased
6
Reduced
9
Closed
5
Top Buys
| 1 |
GSK
GSK
|
$3.77M |
| 2 |
Sarepta Therapeutics
SRPT
|
$2.58M |
| 3 |
Inogen
INGN
|
$2.51M |
| 4 |
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
|
$2.5M |
| 5 |
UnitedHealth
UNH
|
$1.6M |
Top Sells
| 1 |
IPXL
Impax Laboratories, Inc.
IPXL
|
$2.2M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$1.29M |
| 3 |
DaVita
DVA
|
$1.25M |
| 4 |
Incyte
INCY
|
$990K |
| 5 |
Edwards Lifesciences
EW
|
$956K |
Sector Composition
| 1 | Healthcare | 90.17% |
| 2 | Industrials | 6.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Regenxbio
RGNX
$451M
| $239K | 0.33% | +12,398 | New | +$239K |
|
|
CLVS
27
DELISTED
Clovis Oncology, Inc.
CLVS
| $204K | 0.28% | 3,200 -12,632 | -80% | -$805K |
|
|
28
DaVita
DVA
$9.85B
| – | – | -19,451 | Closed | -$1.25M |
|
|
29
Edwards Lifesciences
EW
$47.8B
| – | – | -10,200 | Closed | -$956K |
|
30
Natera
NTRA
$23.1B
| – | – | -59,300 | Closed | -$694K |
|
31
Perrigo
PRGO
$3.27B
| – | – | -10,339 | Closed | -$861K |
|
|
IPXL
32
DELISTED
Impax Laboratories, Inc.
IPXL
| – | – | -166,099 | Closed | -$2.2M |
|